BioNTech (NASDAQ:BNTX) Given Hold Rating at SVB Leerink

BioNTech (NASDAQ:BNTX)‘s stock had its “hold” rating reaffirmed by research analysts at SVB Leerink in a note issued to investors on Thursday, AnalystRatings.com reports.

Several other research analysts also recently issued reports on the company. Wolfe Research began coverage on BioNTech in a research note on Monday. They issued an “outperform” rating and a $248.00 price objective for the company. Canaccord Genuity upped their price objective on BioNTech from $130.00 to $240.00 and gave the company a “buy” rating in a research note on Wednesday, May 12th. Zacks Investment Research upgraded BioNTech from a “sell” rating to a “hold” rating in a report on Wednesday. Bryan, Garnier & Co reiterated a “neutral” rating and issued a $206.00 target price (up from $135.00) on shares of BioNTech in a report on Monday, May 17th. Finally, Berenberg Bank set a $130.00 target price on BioNTech and gave the company a “buy” rating in a report on Tuesday, April 6th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $169.83.

BNTX stock traded up $21.28 during midday trading on Thursday, reaching $280.89. The company had a trading volume of 230,259 shares, compared to its average volume of 2,197,576. The stock has a market capitalization of $67.84 billion, a P/E ratio of 49.20 and a beta of -1.58. The company’s 50 day simple moving average is $217.35. BioNTech has a 1-year low of $54.10 and a 1-year high of $261.77. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.70 and a quick ratio of 2.58.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Sunday, May 9th. The company reported $4.39 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.09 by $1.30. BioNTech had a return on equity of 91.61% and a net margin of 48.40%. The company had revenue of $2.05 billion during the quarter, compared to the consensus estimate of $1.40 billion. The company’s quarterly revenue was up 7294.9% compared to the same quarter last year. Research analysts anticipate that BioNTech will post 31.59 EPS for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BNTX. Baillie Gifford & Co. purchased a new stake in BioNTech in the 1st quarter valued at $735,723,000. Price T Rowe Associates Inc. MD raised its position in BioNTech by 31.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,074,906 shares of the company’s stock valued at $226,559,000 after buying an additional 500,085 shares during the last quarter. DekaBank Deutsche Girozentrale raised its position in BioNTech by 259.3% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 482,377 shares of the company’s stock valued at $52,148,000 after buying an additional 348,124 shares during the last quarter. Coatue Management LLC purchased a new stake in shares of BioNTech during the 1st quarter valued at $37,326,000. Finally, Mitsubishi UFJ Trust & Banking Corp purchased a new stake in shares of BioNTech during the 1st quarter valued at $30,171,000. 12.42% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.

Further Reading: How to Use the New Google Finance Tool

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.